- Ring The Bell
- Posts
- 🏦 Why the Big Banks Are Blossoming Again
🏦 Why the Big Banks Are Blossoming Again
Plus, the companies witnessing insider selling, and more
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
Happy Thursday! Major U.S. banks exceeded fourth-quarter earnings expectations, fueled by strong net interest income and resilient fee revenue, sparking a rally in financial stocks. Here’s how these results could set the stage for further sector gains in 2025. Also, investors should be cautious of these companies seeing insider sells.
—Josh Enomoto
Plus, if you’re looking to invest in the fight against rare diseases, check out today’s sponsor!
MARKET RECAP
Yesterday: Stocks surged Tuesday, with the S&P 500 gaining 1.8% and the Nasdaq rising 2.5%, driven by moderating core CPI inflation and strong earnings reports from major banks. Bond yields fell sharply as disinflationary trends and broad-based corporate profit growth supported a risk-on sentiment heading into 2025.
On Our Radar: After reviewing initial jobless claims and retail sales, analysts will turn to business inventories and home builder confidence reports. On the earnings front, J.B. Hunt Transport is scheduled to disclose its results after the closing bell.
TOP STORY
Big banks crushed Q4 earnings forecasts, fueling the largest one-day rally in financial stocks since late 2024.
SPONSORED CONTENT
Mycosis fungoides is a type of skin cancer that affects the body’s T cells, which are white blood cells intended to protect the body from infection. It is the most common form of cutaneous T-cell lymphoma (CTCL), the category name given to a diverse and complex group of rare skin cancers.
As reported by the Cutaneous Lymphoma Foundation, approximately 3,000 new CTCL cases are reported in the U.S. every year, with as many as 20,000-30,000 living with this chronic, incurable disease.
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, reports it is on the cusp of treating CTCL with its leading product candidate, HyBryte™. To learn more about the company and it’s treatment click here
This is a paid ad. Please see 17b disclosure here for more information.
FIVE ZINGERS
Stand Down: Hamas accepted a draft agreement for a ceasefire in Gaza, which includes the release of several hostages. Discover how defense stocks are reacting to the development.
Big Props: A Kelley Blue Book report ranked some of Tesla's models among the best selling EVs of last year. Learn about the dramatic impact the news had on TSLA stock.
Doom Boom: The Japanese government bond market has been hot recently, with some experts raising alarm. Learn what Euro Pacific Capital chief economist Peter Schiff had to say on the matter.
Unfriendly Skies: Southwest Airlines is being sued by federal agencies for operating "chronically delayed flights." Here's what management said in response to the lawsuit.
Black Gold: Oil prices surged higher on Wednesday amid rising concerns about global supply disruptions. Discover the core catalysts for the robust bullishness.
SPECIAL OFFER
Editor’s Note: Every Thursday, Benzinga Edge members receive the C-Suite Buy of the Week, a report by Tim Melvin detailing the insider buying that, unlike most, is actually worth paying attention to. Here’s a sneak peek at last week’s:
Most of the time, we ignore insider selling. Insiders can sell for a host of reasons, such as estate planning, life changes, and liquidity needs.
At younger, fast-growing companies, insiders are much more likely to be sellers, as insiders cash in returns on their initial investments in the company.
A stock sale by a corporate VP who needs a few hundred grand to pay his kid’s Harvard tuition bill has little to do with the company’s future expectations.
Academic research and practical experience demonstrate that insider or open market purchases are more important than insider selling.
There is, of course, an exception to the rule. When we see a group of insiders selling stocks near 52-week lows, there is valuable information to be gained. It is highly unlikely that they all needed cash for tuition or a dream home at the same time.
SPECIAL OFFER
Get access to actionable insights and exclusive reports pinpointing tomorrow's fastest-growing opportunities while the timing is right. Click to learn exactly when and where to position yourself before the market changes again.
BEFORE YOU GO
Were you forwarded this email? Click here to subscribe.
And be sure to check out our other newsletters:
Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.
Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.
Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property, or delving into the fast-growing world of fractional real estate. Subscribe here.
Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.
Tech Trends: Get the inside scoop on AI, the hottest gadgets, and mind-blowing tech trends. Subscribe here.